Cargando…

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes

BACKGROUND: Clinical application of population pharmacokinetics (popPK) is of increasing interest to patients with hemophilia, providers, and payers. Routine use of popPK profiles in factor replacement prophylaxis decision making has the potential to maintain or improve efficacy and reduce product c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croteau, Stacy E., Wheeler, Allison P., Khan, Osman, Haley, Kristina M., Borst, Alexandra J., Lattimore, Susan, Yeung, Cindy H. T., Iorio, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles: Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040534/ https://www.ncbi.nlm.nih.gov/pubmed/32110764 http://dx.doi.org/10.1002/rth2.12305

Ejemplares similares

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials
por: Khayat, Claudia Djambas, et al.
Publicado: (2022)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A
por: Hiramoto, Takafumi, et al.
Publicado: (2023)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer
por: Becattini, Cecilia, et al.
Publicado: (2022)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients
por: Davila, Jennifer, et al.
Publicado: (2022)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates
por: Price, Victoria E., et al.
Publicado: (2021)

Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
por: Schöchl, Herbert, et al.
Publicado: (2017)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Soluble protein C receptor: why?
por: Geiger, Margarethe
Publicado: (2008)

Screening platelet function in blood donors
por: Pedini, Pascal, et al.
Publicado: (2022)

Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
por: Dover, Saunya, et al.
Publicado: (2020)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Patient selection for hemophilia gene therapy: Real‐life data from a single center
por: Krumb, Evelien, et al.
Publicado: (2021)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia
por: Kwak, Heechun, et al.
Publicado: (2020)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
por: Chan, Anthony K., et al.
Publicado: (2020)

Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations
por: Sadler, Brooke, et al.
Publicado: (2022)

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD
por: Yadegari, Hamideh, et al.
Publicado: (2022)

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A
por: Urasiński, Tomasz, et al.
Publicado: (2023)

Proximity proteomics identifies septins and PAK2 as decisive regulators of actomyosin-mediated expulsion of von Willebrand factor
por: El-Mansi, Sammy, et al.
Publicado: (2023)

Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: Observational study of efficacy and safety for prophylaxis and treatment
por: Lasky, Joseph, et al.
Publicado: (2020)

A single F153Sβ3 mutation causes constitutive integrin αIIbβ3 activation in a variant form of Glanzmann thrombasthenia
por: Koukouritaki, Sevasti B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_46q3egc5fj5ml1b7k7ga0q5fbl